J&J secures injunction against medical device counterfeiter

Johnson & Johnson’s (J&J) subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

J&J unit primed for multi-million dollar damages over counterfeits

4 August 2022 Judge urges $18m award in ‘horrific’ counterfeiting case | Counterfeits were ‘bacterially contaminated’ | Ethicon.

Medtech

Fed Circ denies bid to reverse favourable J&J ruling

15 February 2022 The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed.

Medtech

Fed Circ upholds challenge to J&J robot patent

24 August 2021 The US Court of Appeals for the Federal Circuit has invalidated more claims of a Johnson & Johnson subsidiary’s surgical robot patent following a cross-appeal of a Patent Trial and Appeal Board decision.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

J&J secures injunction against medical device counterfeiter

More on this story

Editor's picks

Editor's picks

More features